Competing interests
ONCOLOGY
Steffen Koschmieder reports funding from Novartis, Bristol-Myers Squibb, AOP Pharma, Janssen, Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, Sierra Oncology, GSK, Abbvie; patent für BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, GSK, Abbvie; and other financial support (e.g. travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Karthos, Sierra Oncology, Imago Bioscience, GSK, Abbvie.Susanne Isfort reports advisory board honoraria from Pfizer, Incyte, and Novartis,honoraria from Novartis, BMS, Pfizer, Incyte, Abbvie, AOP Orphan and other financial support (e.g. travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, Hexal and AOP Orphan.Heike Pahl reports advisory board honoraria from Novartis and AOP Pharma.